ArticleThe Lancet regional health. Western Pacific2024
Sociodemographic correlates with prevalence of comorbidities in patients with chronic obstructive pulmonary disease: a study from a Chinese National Survey.
Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of integrated care on patients with COPD and comorbidities: a systematic review.Therapeutic advances in respiratory diseasePooled it
- Cardiovascular components of the COTE index predict acute exacerbations and healthcare costs in patients with chronic obstructive pulmonary disease: a nationwide linked cohort study.Respiratory research · 2026Article
- Article
- Developing and testing bolt-on enhanced EQ-5D-5L for assessing Chinese patients with chronic obstructive pulmonary disease: a mixed-methods study protocol.BMJ open respiratory research · 2026Article
- Profiles and Disease Burden of Patients with COPD Initiating Triple Therapy in China.International journal of chronic obstructive pulmonary disease · 2026Observational
- Coronary heart disease and chronic obstructive pulmonary disease prevalence and temporal trends among United States adults: a national population-based study.Frontiers in epidemiology · 2026Article
- Sociodemographic Determinants of Hospitalized Exacerbations in Exposure-Defined COPD Phenotypes: A Nationwide Prospective Cohort Study in China.International journal of chronic obstructive pulmonary disease · 2026Article
- Inhaled Targeted Nano-Drug Delivery Systems for COPD: Precision Solutions to Clinical Barriers.International journal of nanomedicine · 2026Review
- Correlation between questionnaire on air pollution-related factors and chronic respiratory diseases: a case study of Minhang District, Shanghai.BMC public health · 2025Article
- Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Association between multimorbidity and disability among elderly with chronic obstructive pulmonary disease in Shanghai, China: a cross-sectional study.BMC geriatrics · 2025Article
- Increased in-hospital mortality and readmission risk associated with cardiovascular and cerebrovascular comorbidities in acute exacerbation of COPD patients.BMJ open respiratory research · 2025Article
- Cost-effectiveness of chronic obstructive pulmonary disease population screening in China: based on individual data from WHO Collaborating Centre-initiated 'Enjoying Breathing Program'.BMC public health · 2025Article
- COTE and Pulmonary Comorbidities Predict Moderate-to-Severe Acute Exacerbation and Hospitalization in COPD.International journal of chronic obstructive pulmonary disease · 2025Article
- Assessing Medication Literacy and Its Determinants in Chinese Patients with Multimorbidity.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: An increase in the prevalence of comorbidities has been reported in patients with chronic obstructive pulmonary disease (COPD). However, contemporary estimates of the overall prevalence of the sociodemographic correlates of COPD comorbidities are scarce and inconsistent in China. This study aimed to investigate the prevalence of sociodemographic correlates of comorbidities in patients with COPD across China. Methods: This was a cross-sectional study. We used data from the Enjoying Breathing Program between May 2020 and April 2022. Participants with COPD from 17 provinces (or equivalent) were included. Comorbidity clusters were stratified based on the number of comorbidities per person. Univariable and multivariable analyses were used to determine the sociodemographic associations of patients with COPD with specific clusters of comorbidities after adjusting for age, sex, and other prespecified covariates. Tetrachoric correlation analyses were performed to determine the associations between specific comorbidities. Findings: A total of 3913 participants with COPD were included, of whom 1744 (44.7%) had at least one comorbidity; 25.4% had one comorbid disease, 12.9% had two, and 6.4% had three or more concurrent diseases. The most common comorbidities were hypertension (17.8%), asthma (9.9%), bronchiectasis (8.2%), diabetes (8.2%), and coronary artery disease (7.7%). In the logistic regression models adjusted for a broad set of factors, patients with COPD residing in the east region of China and having health insurance experienced a decreased likelihood of comorbidities (from OR = 0.70 [95% confidence interval [CI], 0.53-0.93] to OR = 0.50 [95% CI, 0.25-0.99]). However, patients over 80 years had increased risk (OR 1.43 [95% CI 1.01-2.03]), as did those in all Modified Medical Research Council (mMRC) grade categories (grade 1: OR = 1.30 [95% CI, 1.02-1.65]; grade 2: OR = 1.39 [95% CI, 1.07-1.8]; grade 3: OR = 1.67 [95% CI, 1.23-2.26]; and grade 4: OR = 1.81 [95% CI, 1.00-3.28]) and in Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2 classification (OR = 1.30 [95% CI, 1.03-1.65]) relative to their respective references. The associations observed in these subgroups were consistent regardless of the number of comorbidities per person. Tetrachoric correlations demonstrated negative associations in pairwise comparisons of the top five comorbidities, ranging from -0.03 to -0.31 (p < 0.001 in all groups). Interpretation: In China, comorbidities are highly prevalent among patients with COPD, with older age, higher mMRC grade, and lung function decline being the major risk factors. Studies with larger sample sizes are required to elucidate the complex mechanisms underlying COPD comorbidities. Funding: This study was funded by CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-049 and 2022-I2M-C&T-B-107).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.